Cargando…
Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors
Searching for targets that allow pharmacological inhibition of cell proliferation in over-proliferative states, such as cancer, leads us to finely understand the complex mechanisms orchestrating the perfect control of mitosis number, frequency and pace as well as the molecular arrangements that indu...
Autores principales: | Montor, Wagner Ricardo, Salas, Andrei Ronaldo Oliveira Silva Escartin, Melo, Fabiana Henriques Machado de |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817866/ https://www.ncbi.nlm.nih.gov/pubmed/29455659 http://dx.doi.org/10.1186/s12943-018-0792-2 |
Ejemplares similares
-
Cancer Chemoprevention: Classic and Epigenetic Mechanisms Inhibiting Tumorigenesis. What Have We Learned So Far?
por: de Melo, Fabiana Henriques Machado, et al.
Publicado: (2018) -
The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer
por: Cerrato, Aniello, et al.
Publicado: (2018) -
Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter?
por: Qin, Anna, et al.
Publicado: (2021) -
The role of RICTOR downstream of receptor tyrosine kinase in cancers
por: Jebali, Ahlem, et al.
Publicado: (2018) -
How many kinases are druggable? A review of our current understanding
por: Anderson, Brian, et al.
Publicado: (2023)